Christopher E. Lominska
Expertise in
28
conditions

Dr. Christopher E. Lominska

Radiation Oncology
4001 Rainbow Boulevard, 
Kansas City, KS 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
21 Years of Experience
Expertise in
28
conditions
4001 Rainbow Boulevard, 
Kansas City, KS 

Overview

Christopher Lominska is a Radiation Oncologist in Kansas City, Kansas. Dr. Lominska has been practicing medicine for over 21 years is highly rated in 28 conditions, according to our data. His top areas of expertise are Laryngeal Cancer, Oral Squamous Cell Carcinoma, Posterior Fossa Tumor, and Bone Tumor. Dr. Lominska is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Columbia University Vagelos College Of Physicians And Surgeons, Doctor Of Medicine, 2005

Residency

Georgetown University Hospital, Radiation Oncology, 2010

Specialties

Radiation Oncology

Board Certifications

American Board Of Radiology, Radiation Oncology - 2011

Hospital Affiliations

Olathe Medical Center
University Of Kansas Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Richard and Annette Bloch Radiation Oncology Pavilion
4001 Rainbow Boulevard, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Cisplatin, Pembrolizumab
Study Phase: Phase 2
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
Enrollment Status: Recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Tempol
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

26 Total Publications

Logistic Model in Clinical and Health Research-the Elephant and Blind Men.
Logistic Model in Clinical and Health Research-the Elephant and Blind Men.
Journal: American journal of clinical oncology
Published: September 15, 2025
Similar Doctors
Xinglei Shen
Expertise in
15
conditions
Dr. Xinglei Shen
Radiation Oncology
Expertise in
15
conditions
Dr. Xinglei Shen
Radiation Oncology

Richard And Annette Bloch Radiation Oncology Pavilion

4001 Rainbow Boulevard, 
Kansas City, KS 
 (4.1 miles away)
913-588-1227
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Xinglei Shen is a Radiation Oncologist in Kansas City, Kansas. Dr. Shen has been practicing medicine for over 19 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Prostatectomy, and Orchiectomy. Dr. Shen is currently accepting new patients.

Fen Wang
Expertise in
44
conditions
Dr. Fen Wang
Radiation Oncology
Expertise in
44
conditions
Dr. Fen Wang
Radiation Oncology

Richard And Annette Bloch Radiation Oncology Pavilion

4001 Rainbow Boulevard, 
Kansas City, KS 
 (4.1 miles away)
913-588-1227
Experience:
42+ years
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Fen Wang is a Radiation Oncologist in Kansas City, Kansas. Dr. Wang has been practicing medicine for over 42 years is highly rated in 44 conditions, according to our data. His top areas of expertise are Meningioma, Lung Cancer, Pleuropulmonary Blastoma, and Posterior Fossa Tumor. Dr. Wang is currently accepting new patients.

Ronny L. Rotondo
Expertise in
35
conditions
Dr. Ronny L. Rotondo
Radiation Oncology
Expertise in
35
conditions
Dr. Ronny L. Rotondo
Radiation Oncology

Richard And Annette Bloch Radiation Oncology Pavilion

4001 Rainbow Boulevard, 
Kansas City, KS 
 (4.1 miles away)
913-588-1227
Experience:
21+ years
Languages Spoken:
English, French, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronny Rotondo is a Radiation Oncologist in Kansas City, Kansas. Dr. Rotondo has been practicing medicine for over 21 years is highly rated in 35 conditions, according to our data. His top areas of expertise are Chordoma, Adult Soft Tissue Sarcoma, Bone Tumor, and Ewing Sarcoma. Dr. Rotondo is currently accepting new patients.

Frequently Asked Questions about Dr. Christopher E. Lominska

How do I make an appointment with Dr. Christopher E. Lominska?

You can book an appointment with Dr. Christopher E. Lominska by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christopher E. Lominska a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christopher E. Lominska is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christopher E. Lominska specialize in?

While Dr. Christopher E. Lominska is a Radiation Oncology, they have specific expertise in Laryngeal Cancer, Oral Squamous Cell Carcinoma, and Posterior Fossa Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Christopher E. Lominska participate in research or clinical trials?

Yes. Dr. Christopher E. Lominska has published 26 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Christopher E. Lominska's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christopher E. Lominska accept my insurance?

Dr. Christopher E. Lominska accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lominska's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile